Trial
NCT06092216
Spesolimab in Pyoderma Gangrenosum
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Icahn School of Medicine at Mount Sinai
Collaborators
Boehringer Ingelheim
Condition
Pyoderma Gangrenosum
Intervention
Spesolimab
Why stopped
The funding sponsor terminated our study and will conduct a multicenter national study in its place.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-31